These studies in murine tumor models clearly suggest that either the exogenous administration of recombinant TIMP-2 or the use of nanoparticle-based delivery vehicle which can deliver TIMP-2 to tumor sites may have a potential for therapeutic utility in cancer where TIMP-2 is suppressed. This evidence concerns the gene TIMP2 and neoplasm.